The process of TIL therapy is complex and requires the coordination of multiple specialties at authorized treatment centers, ...

Osvyrti and Jubereq are FDA-approved denosumab biosimilars for osteoporosis and cancer-related skeletal events, ...

Zidesamtinib targets ROS1+ NSCLC patients with prior TKI treatment, addressing CNS-penetrant treatment challenges and ...

The second study presented at the SITC meeting focuses on a “next-generation” approach following TIL therapy, utilizing ...

Safety concerns included a 58% rate of treatment-related adverse events, with severe cases like immune-related colitis and a ...

During a live event, Hannah Choe, MD, discussed options for steroid-resistant cGVHD based on organ involvement, efficacy, and safety profiles. The management of steroid-refractory chronic ...

High CD8-positive T cell infiltration is linked to shorter PFS in epithelial ovarian cancer patients treated with bevacizumab ...

The FDA has granted full approval to tarlatamab-dlle (Imdelltra) for the treatment of adult patients with extensive stage ...

Neladalkib showed a 31% ORR in TKI-pretreated ALK+ NSCLC patients, with durable responses at 12 and 18 months.

The FDA has granted an accelerated approval to sevabertinib (Hyrnuo) for the treatment of adult patients with previously ...

The ANDROMEDA trial showed improved MOD-PFS and OS with daratumumab and hyaluronidase plus VCd compared to VCd alone in light ...

Final 5-year data from the phase 2 2102-HEM-101 trial (NCT02719574) show that olutasidenib (Rezlidhia) delivered sustained ...